Synairgen plc (SYGGF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Synairgen plc (SYGGF) trades at $0.0001. Synairgen plc is a biotechnology company focused on discovering and developing drugs for respiratory diseases. Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for SYGGF: SYGGF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SYGGF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SYGGF: 2/3 scored disciplines lean bearish. Dominant signal: Ken Griffin bearish.
How is this calculated? →Synairgen plc (SYGGF) Healthcare & Pipeline Overview
Synairgen plc, a UK-based biotechnology firm, specializes in developing inhaled interferon beta (IFN-ß) therapeutics for respiratory diseases, including COVID-19, asthma, and COPD. Their lead asset, SNG001, is undergoing clinical trials, positioning the company within the competitive respiratory therapeutics market, with a focus on addressing unmet needs in viral-induced exacerbations.
What Is the Investment Thesis for SYGGF?
Synairgen plc presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's value hinges primarily on the successful development and commercialization of SNG001, its inhaled interferon beta (IFN-ß) therapy. While initial trials for COVID-19 were not as promising as hoped, ongoing Phase II clinical trials for asthma and COPD could provide significant upside if successful. Positive data from these trials could lead to partnerships or potential acquisition. However, the company's limited financial resources and reliance on a single key asset create substantial risk. Investors should closely monitor clinical trial results and the company's ability to secure additional funding or partnerships to mitigate these risks. The current P/E ratio of -0.23 reflects the company's lack of profitability.
Based on FMP financials and quantitative analysis
SYGGF Key Highlights
Synairgen is focused on developing inhaled interferon beta (IFN-ß) therapies for respiratory diseases.
- SNG001, the company's lead product, is currently in Phase II clinical trials for asthma and COPD.
- The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor for IPF.
- Synairgen has a market capitalization of $0.00B, reflecting its early-stage development status.
- The company's beta of 1.89 indicates higher volatility compared to the overall market.
Who Are SYGGF's Competitors?
SYGGF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CLCS Cell Source, Inc. | $0.65 | +0.00% | $44.0M | 45 |
| IMMVF Immunovia AB (publ) | $0.02 | +0.00% | $6.11M | 39 |
| IMUC EOM Pharmaceuticals Holdings, Inc. | $0.13 | -5.71% | $16.7M | 48 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SYGGF's Key Strengths?
Focus on respiratory diseases with high unmet needs.
- Proprietary inhaled interferon beta (IFN-ß) technology.
- Collaboration agreement with Pharmaxis Ltd.
- Experienced management team in drug development.
What Are SYGGF's Weaknesses?
Limited financial resources.
- Reliance on a single key asset (SNG001).
- High risk of clinical trial failures.
- Lack of commercialization infrastructure.
What Could Drive SYGGF Stock Higher?
Results from Phase II clinical trials for SNG001 in asthma (expected within 12-18 months).
- Results from Phase II clinical trials for SNG001 in COPD (expected within 12-18 months).
- Development of the LOXL2 inhibitor for IPF in collaboration with Pharmaxis Ltd.
- Potential for partnerships and licensing agreements with larger pharmaceutical companies.
- Expansion of SNG001 into new indications (e.g., influenza, RSV).
What Are the Key Risks for SYGGF?
Financial-distress signal — its Altman Z-Score of -27.48 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-51.1%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
- Failure of Phase II clinical trials for SNG001 in asthma and COPD.
- Competition from other companies developing respiratory disease treatments.
- Limited financial resources and reliance on a single key asset (SNG001).
- Regulatory hurdles and delays in drug approval.
- Negative publicity or safety concerns related to SNG001.
What Are the Growth Opportunities for SYGGF?
- Expansion of SNG001 into new indications: Synairgen has the opportunity to expand the use of SNG001 beyond its current focus on asthma and COPD. Exploring its efficacy in other respiratory viral infections, such as influenza or RSV, could significantly broaden its market potential. This expansion would require further clinical trials and regulatory approvals.
- Partnerships and licensing agreements: Synairgen can pursue partnerships and licensing agreements with larger pharmaceutical companies to accelerate the development and commercialization of its products. Collaborating with established players can provide access to resources, expertise, and distribution networks, increasing the likelihood of successful market entry. Such partnerships can also generate upfront payments and milestone payments, providing much-needed funding for Synairgen's research and development activities. The timeline for securing such agreements is variable but could materialize within the next 1-3 years.
- Positive Phase II trial results: Successful completion of Phase II clinical trials for SNG001 in asthma and COPD is a critical growth catalyst for Synairgen. Positive data demonstrating efficacy and safety could significantly increase investor confidence and attract further funding or acquisition interest. The results of these trials are expected within the next 12-18 months and will be a key determinant of the company's future prospects. A positive outcome would validate the company's technology platform and de-risk the investment proposition.
- Development of the LOXL2 inhibitor for IPF: Synairgen's LOXL2 inhibitor, currently in development through a collaboration with Pharmaxis Ltd., represents another potential growth driver. Idiopathic pulmonary fibrosis (IPF) is a progressive and debilitating lung disease with limited treatment options. A successful LOXL2 inhibitor could address a significant unmet need and generate substantial revenue. The timeline for this program is longer, with clinical trials likely to extend over several years, but the potential market opportunity is significant.
- Geographic expansion: Synairgen can expand its geographic reach by seeking regulatory approvals and commercializing its products in new markets. Initially focusing on major markets like the US and Europe, and then expanding into emerging markets, could significantly increase its revenue potential. This expansion would require significant investment in regulatory affairs, marketing, and distribution, but could yield substantial returns in the long run. The timeline for geographic expansion would depend on the progress of clinical trials and regulatory approvals in each target market.
What Are SYGGF's Competitive Advantages?
- Intellectual property protection: Patents on its inhaled interferon beta (IFN-ß) technology and LOXL2 inhibitor provide a degree of exclusivity.
- Clinical trial expertise: Experience in conducting clinical trials for respiratory disease treatments.
- Collaboration agreements: Partnerships with companies like Pharmaxis Ltd. provide access to additional expertise and resources.
What Does SYGGF Do?
Synairgen plc, founded in 2004 and headquartered in Southampton, UK, is a drug discovery and development company focused on respiratory diseases. The company's primary focus is on developing inhaled interferon beta (IFN-ß) therapies for various respiratory conditions. Their lead product, SNG001, is an inhaled formulation of IFN-ß initially developed as a potential treatment for COVID-19. While its initial promise in COVID-19 faced setbacks, Synairgen is now exploring SNG001's potential in treating other respiratory illnesses, including asthma and chronic obstructive pulmonary disease (COPD). Synairgen's pipeline also includes a LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF), developed through a licensing and collaboration agreement with Pharmaxis Ltd. The company operates with a relatively small team of 36 employees, reflecting its focus on research and development activities. Synairgen aims to address the significant unmet needs in respiratory disease treatment by developing novel therapies that target the underlying mechanisms of viral-induced exacerbations and chronic lung conditions.
What Products and Services Does SYGGF Offer?
- Discovers and develops drugs for respiratory diseases.
- Develops SNG001, an inhaled interferon beta for the treatment of COVID-19.
- Develops inhaled interferon beta (IFN-ß) for the treatment of asthma caused by the common cold and flu.
- Develops IFN-ß for the treatment or prevention of chronic obstructive pulmonary disease.
- Develops LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease.
- Collaborates with Pharmaxis Ltd. to develop a LOXL2 inhibitor.
How Does SYGGF Make Money?
- Focuses on research and development of novel therapeutics for respiratory diseases.
- Seeks to license or partner its drug candidates with larger pharmaceutical companies for commercialization.
- Generates revenue through licensing agreements, milestone payments, and potential royalties on future sales.
What Industry Does SYGGF Operate In?
Synairgen plc operates within the competitive biotechnology industry, specifically targeting the respiratory therapeutics market. This market is characterized by a high unmet need for effective treatments for diseases like asthma, COPD, and viral-induced respiratory illnesses. The industry is driven by innovation, with companies constantly seeking novel therapies and drug delivery methods. Synairgen's focus on inhaled interferon beta (IFN-ß) positions it within the broader landscape of antiviral and anti-inflammatory therapies. Competitors include companies developing similar treatments or targeting the same disease areas with different approaches. The biotechnology industry is subject to stringent regulatory requirements and faces significant risks associated with clinical trial outcomes and drug approval processes.
Who Are SYGGF's Key Customers?
- Pharmaceutical companies seeking to license or acquire novel respiratory therapeutics.
- Patients suffering from respiratory diseases such as asthma, COPD, COVID-19, and IPF.
- Healthcare providers who prescribe and administer respiratory medications.
Company Profile
Synairgen plc operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Southampton, GB. The company is led by CEO Joseph Tregonning Colliver. SYGGF has traded publicly since 2020.
Key Financial Metrics
Return on equity for Synairgen plc stands at -51.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -59.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -71.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 9.01 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
Synairgen plc's Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -27.48 places it in the distress zone, a signal of elevated financial risk.
SYGGF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Synairgen's recent insider buying suggests those in the know see long-term value, a potential confidence signal.
- The community buzz seems to be cautiously optimistic about their pipeline, hinting at future potential.
- Market perception appears to be shifting, with some viewing Synairgen as undervalued given its research focus. This is similar to how early biotech firms were viewed before major breakthroughs.
- Recent developments indicate increased interest in respiratory therapeutics, potentially benefiting Synairgen.
Bear Case
- Community sentiment shows lingering concerns about the pace of Synairgen's clinical trials, creating uncertainty.
- Market perception reveals skepticism regarding the commercial viability of their current lead drug, similar to other single-drug companies.
- Recent insider selling, even if unrelated to company performance, may raise eyebrows among investors.
- The overall market sentiment in the biotech sector has been volatile, creating headwinds for Synairgen, much like the dot-com bubble's impact on tech stocks.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SYGGF Latest News
No recent news available for SYGGF.
SYGGF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SYGGF.
Price Targets
Wall Street price target analysis for SYGGF.
SYGGF MoonshotScore
What does this score mean?
The MoonshotScore rates SYGGF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Joseph Tregonning Colliver
Unknown
Information on Joseph Tregonning Colliver's background is limited. He is currently managing 36 employees at Synairgen plc. Further details regarding his career history, education, and previous roles are not available in the provided data.
Track Record: Due to the limited information available, it is not possible to assess Joseph Tregonning Colliver's track record at Synairgen plc. Key achievements, strategic decisions, and company milestones under his leadership cannot be determined from the provided data.
SYGGF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Synairgen plc may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often associated with higher risk and greater potential for volatility due to the lack of stringent listing requirements and readily available information.
- OTC Tier: OTC Other
- Limited financial disclosure: The lack of comprehensive financial reporting can make it difficult to assess the company's financial health and performance.
- Lower liquidity: Trading volumes may be low, leading to wider bid-ask spreads and potential price volatility.
- Less regulatory oversight: OTC-listed companies are subject to less regulatory scrutiny than exchange-listed companies, increasing the risk of fraud or mismanagement.
- Potential for delisting: Failure to meet minimum listing requirements could result in delisting from the OTC market.
- Information scarcity: Limited analyst coverage and news flow can make it challenging to stay informed about the company's activities and prospects.
- Verify the company's registration and good standing with regulatory authorities.
- Review available financial statements and assess the company's financial health.
- Research the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Assess the potential risks and challenges facing the company.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Established business operations since 2004.
- Focus on developing drugs for respiratory diseases, addressing a clear market need.
- Collaboration agreement with Pharmaxis Ltd.
- Presence of intellectual property protection (patents).
Common Questions About SYGGF (Healthcare)
What does Synairgen plc do?
Synairgen plc is a biotechnology company focused on discovering and developing drugs for respiratory diseases. Their lead product, SNG001, is an inhaled formulation of interferon beta (IFN-ß) initially developed for COVID-19.
What do analysts say about SYGGF stock?
As of 2026-03-16, analyst coverage for SYGGF is limited due to its OTC listing and small market capitalization. Key valuation metrics, such as the P/E ratio of -0.23, reflect the company's current lack of profitability. The company's future prospects depend heavily on the success of its clinical trials for SNG001 in asthma and COPD. Investors should conduct their own thorough research and consider the high-risk, high-reward nature of this investment.
What are the main risks for SYGGF?
The main risks for Synairgen plc include the potential failure of clinical trials for SNG001, competition from other companies developing respiratory disease treatments, limited financial resources, regulatory hurdles, and potential safety concerns related to SNG001. As an OTC-listed company, SYGGF also faces risks associated with lower liquidity, less regulatory oversight, and limited financial disclosure. These factors contribute to the high-risk profile of this investment.
What are the key factors to evaluate for SYGGF?
Evaluate SYGGF on fundamentals, analyst consensus, and risk factors. Synairgen plc presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does SYGGF data refresh on this page?
SYGGF's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SYGGF's recent stock price performance?
Synairgen plc (SYGGF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on respiratory diseases with high unmet needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SYGGF overvalued or undervalued right now?
Synairgen plc (SYGGF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SYGGF before investing?
Before investing in Synairgen plc (SYGGF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on CEO's background and track record.
- OTC market data may be less reliable than exchange-listed data.